Integra Lifesciences Holdings (IART) Non-Current Deferred Tax Liability (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Non-Current Deferred Tax Liability data on file, last reported at $6.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deferred Tax Liability fell 89.33% year-over-year to $6.1 million; the trailing twelve-month figure through Mar 2026 stood at $6.1 million (down 89.33% YoY), and the FY2025 full-year result was $5.7 million, down 90.69% from the prior year.
• Non-Current Deferred Tax Liability grew to $6.1 million in Q1 2026, from $5.7 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $86.5 million in Q2 2024 to a low of $5.7 million in Q4 2025.
• A 5-year average of $54.6 million and a median of $60.8 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• Peak annual rise in Non-Current Deferred Tax Liability reached 83.2% in 2025, while the deepest fall reached 90.69% in 2025.
• Tracing IART's Non-Current Deferred Tax Liability over 5 years: stood at $63.3 million in 2022, then slumped by 44.24% to $35.3 million in 2023, then soared by 72.25% to $60.8 million in 2024, then slumped by 90.69% to $5.7 million in 2025, then climbed by 8.46% to $6.1 million in 2026.
• Business Quant data shows IART's Non-Current Deferred Tax Liability at $6.1 million in Q1 2026, $5.7 million in Q4 2025, and $58.3 million in Q3 2025.